NCT00749216已完成2 期
Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD in Japanese population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or non-fertile women, at least 50 years of age.(Women who are not surgically sterilized must be post-menopausal for at least 1 year.)
- •Patients with mild to moderate AD by following disease diagnostic criteria
- •National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
- •Modified Hachinski Ischemia Scale score of ≦ 4
- •Folstein Mini-Mental State Examination (MMSE) score of 15 through 26
- •Geriatric Depression Scale (GDS) score of ≦ 10 on the staff-administered short form
排除标准
- •Patients who don't have a reliable caregiver who is in frequent contact with the patient, who will accompany the patient to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications.
- •Patients who have an MRI or CT scan since the onset of symptoms of AD that is inconsistent with a diagnosis of AD.
- •Patients who have received acetylcholinesterase inhibitors (AChEIs) or memantine for less than 4 months, or have less than 2 months of stable therapy on these treatments.
- •Patients who have current serious or unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator or subinvestigator(s)'s opinion, could interfere with the analyses of safety and efficacy in this study.
- •Patients who have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness within the last 5 years, or multiple episodes of head trauma.
- •Patients who have a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA post-resection.
- •Patients who have allergies to humanized monoclonal antibodies.
- •Patients who have a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA post-resection.
- •Patients who have ECG abnormalities obtained that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study, including QTc prolongation (Bazett's corrected QTc interval, QTcB; males >435 msec or females >455 msec) or abnormally wide QRS complexes (resulting from bundle-branch blocks, interventricular conduction delays, or pacemakers).
- •Patients who have a current, required use or expected use of excluded drugs through the duration(These drugs include typical neuroleptics (antipsychotics). In addition, typical neuroleptics may not be taken within 4 weeks.
- •Patients who are currently taking chronic medications that affect central nervous system (CNS) function, and are not dose-stabilized for at least 4 weeks.
- •Patients who have a ventriculoperitoneal shunt or gamma globulin (IgG) therapy within the last year.
- •Patients who have previously completed or withdrawn from this study or previous participation in any other study investigating active immunization against Aβ.
- •Patients who have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker.
- •Patients who weigh less than 40 kg.
研究组 & 干预措施
QW
Experimental
IV infusion of 400mg once each week for 2 months
干预措施: Solanezumab (Drug)
Q4W
Experimental
IV infusion of 400mg once every four weeks for 2 months
干预措施: Solanezumab (Drug)
Q8W
Experimental
IV infusion of 400mg once every eight weeks for 2 months
干预措施: Solanezumab (Drug)
结局指标
主要结局
Adverse events
时间窗: 6 months
次要结局
- Changes in the extended ADAS-Cog stand for Alzheimer's Disease Assessment Scale-Cognitive subscale(6 months)
- pharmacodynamic of Aβ1-40 and Aβ1-42(6 months)
- Pharmacokinetics(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Dose Ethnobridging PK Study in Healthy SubjectsInflammatory Bowel DiseasesIBDNCT03750565Theravance Biopharma60
已完成
1 期
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT04276428Eli Lilly and Company28
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate AsthmaAsthmaNCT01370317Merck Sharp & Dohme LLC27
终止
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseNCT02220738AbbVie19
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising DosesHealthyNCT01505894Boehringer Ingelheim83